Literature DB >> 26611550

Corticosteroids in Lupus.

Shanthini Kasturi1, Lisa R Sammaritano2.   

Abstract

Corticosteroids are the mainstay of treatment of systemic lupus erythematosus, with most patients receiving them at some point in the course of their disease. Corticosteroid use is associated with significant side effects, including infections, hypertension, hyperglycemia, osteoporosis, avascular necrosis, myopathy, cataracts, and glaucoma. Dosing regimens are based on limited data, with the goal of adequately controlling inflammatory symptoms while minimizing steroid exposure in order to reduce adverse effects.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corticosteroids; Glucocorticoids; Methylprednisolone; Prednisone; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 26611550     DOI: 10.1016/j.rdc.2015.08.007

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  18 in total

1.  Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.

Authors:  S Kabadi; J Yeaw; A K Bacani; E Tafesse; K Bos; S Karkare; M DeKoven; E R Vina
Journal:  Lupus       Date:  2018-08-01       Impact factor: 2.911

Review 2.  Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus.

Authors:  Jianghong Deng; Nathalie E Chalhoub; Catherine M Sherwin; Caifeng Li; Hermine I Brunner
Journal:  Semin Arthritis Rheum       Date:  2019-03-16       Impact factor: 5.532

3.  Pharmacological potentiation of the efferent vagus nerve attenuates blood pressure and renal injury in a murine model of systemic lupus erythematosus.

Authors:  Grace S Pham; Lei A Wang; Keisa W Mathis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-10-17       Impact factor: 3.619

4.  Selenium supplementation suppresses immunological and serological features of lupus in B6.Sle1b mice.

Authors:  Chetna Soni; Indu Sinha; Melinda J Fasnacht; Nancy J Olsen; Ziaur S M Rahman; Raghu Sinha
Journal:  Autoimmunity       Date:  2019-04-22       Impact factor: 2.815

Review 5.  An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus.

Authors:  Amit Thakral; Marisa S Klein-Gitelman
Journal:  Rheumatol Ther       Date:  2016-09-30

Review 6.  Shrinking lung syndrome in systemic lupus erythematosus: A case series and review of the literature.

Authors:  Helena Borrell; Javier Narváez; Juan José Alegre; Ivan Castellví; Francesca Mitjavila; María Aparicio; Eulàlia Armengol; María Molina-Molina; Joan M Nolla
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

7.  Increased Macroautophagy in Interferon-Gamma-Producing T Cells from Patients with Newly Diagnosed Systemic Lupus Erythematosus.

Authors:  Xiong-Yan Luo; Jia-Li Yuan; Jing Liu; Cai-Nan Luo; Ming-Hui Yang; Qin Wei; Min Yang; Yong Chen; Yi Liu; Guo-Hua Yuan
Journal:  Chin Med J (Engl)       Date:  2018-07-05       Impact factor: 2.628

8.  Effects of Gasdermin D in Modulating Murine Lupus and its Associated Organ Damage.

Authors:  Xinghao Wang; Luz P Blanco; Carmelo Carmona-Rivera; Shuichiro Nakabo; Hege L Pedersen; Zu-Xi Yu; Mariana J Kaplan
Journal:  Arthritis Rheumatol       Date:  2020-10-17       Impact factor: 15.483

9.  Lipopolysaccharide Challenge Reveals Hypothalamic-Pituitary-Adrenal Axis Dysfunction in Murine Systemic Lupus Erythematosus.

Authors:  Grace S Pham; Keisa W Mathis
Journal:  Brain Sci       Date:  2018-10-04

10.  Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre.

Authors:  Christine Anastasiou; Olivia Dulai; Amrutha Baskaran; James Proudfoot; Samuel Verhaegen; Kenneth Kalunian
Journal:  Lupus Sci Med       Date:  2018-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.